Comparative of the Effect of Sorafenib and 125Ⅰ Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer Patients with Radioactive Iodine
Objective:To investigate the effect of sorafenib and 125Ⅰ particle implantation in patients with radioiodine-refractory differentiated thyroid cancer.Methods:A total of 56 patients with radioactive iodine-refractory differentiated thyroid cancer diagnosed and treated in our hospital from February 2020 to May 2022 were selected as the research objects.According to the random number table method,they were divided into sorafenib group and implantation group,with 28 patients in each group.The implantation group was treated with 125Ⅰ seed implantation,and the sorafenib group was treated with sorafenib.The disease control rate,incidence of toxic and side effects and serum factor expression were compared between the two groups after 3 months of treatment.Result:After 3 months of treatment,the disease control rate of the sorafenib group was 85.72%,which was higher than 67.86%of the implantation group(P<0.05).There was no significant difference in the incidence of adverse reactions between the sorafenib group and the implantation group(P>0.05).The serum levels of IL-6 and IL-8 in the sorafenib group were lower than those in the implantation group(P<0.05).Conclusion:Compared with 125Ⅰ particle implantation treatment,sorafenib treatment can inhibit tumor progression in patients with thyroid cancer,reduce clinical symptoms,and has a high safety profile.
Sorafenib125Ⅰ seed implantation therapyThyroid cancer
NETL
NSTL
万方数据
